56,945 Shares in Aurinia Pharmaceuticals Inc $AUPH Bought by Sanctuary Advisors LLC

by · The Markets Daily

Sanctuary Advisors LLC purchased a new position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 56,945 shares of the biotechnology company’s stock, valued at approximately $966,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AUPH. Royal Bank of Canada raised its holdings in shares of Aurinia Pharmaceuticals by 65.3% during the first quarter. Royal Bank of Canada now owns 367,661 shares of the biotechnology company’s stock valued at $2,956,000 after purchasing an additional 145,179 shares during the period. AQR Capital Management LLC grew its stake in shares of Aurinia Pharmaceuticals by 8.7% in the 1st quarter. AQR Capital Management LLC now owns 503,543 shares of the biotechnology company’s stock valued at $4,048,000 after buying an additional 40,380 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Aurinia Pharmaceuticals by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company’s stock valued at $642,000 after buying an additional 3,497 shares during the period. Creative Planning increased its position in Aurinia Pharmaceuticals by 21.0% in the 2nd quarter. Creative Planning now owns 20,699 shares of the biotechnology company’s stock valued at $175,000 after buying an additional 3,594 shares in the last quarter. Finally, Legal & General Group Plc increased its position in Aurinia Pharmaceuticals by 16.5% in the 2nd quarter. Legal & General Group Plc now owns 141,492 shares of the biotechnology company’s stock valued at $1,201,000 after buying an additional 20,027 shares in the last quarter. 36.83% of the stock is owned by institutional investors.

Insider Activity at Aurinia Pharmaceuticals

In related news, CEO Kevin Tang bought 206,005 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were bought at an average price of $15.28 per share, for a total transaction of $3,147,756.40. Following the completion of the acquisition, the chief executive officer directly owned 13,044,106 shares of the company’s stock, valued at $199,313,939.68. This trade represents a 1.60% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Royal Bank Of Canada increased their price target on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a “sector perform” rating in a report on Friday, August 7th. Weiss Ratings restated a “hold (c+)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, August 12th. Zacks Research downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Bloom Burton raised Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 20th. Finally, Wall Street Zen cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Aurinia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $17.67.

View Our Latest Report on AUPH

Aurinia Pharmaceuticals Trading Down 0.4%

AUPH opened at $16.48 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.42 and a quick ratio of 4.97. Aurinia Pharmaceuticals Inc has a fifty-two week low of $10.34 and a fifty-two week high of $19.25. The firm has a market capitalization of $2.19 billion, a PE ratio of 7.20 and a beta of 1.42. The company’s 50-day moving average is $15.98 and its 200 day moving average is $15.49.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.04. The business had revenue of $58.57 million for the quarter, compared to analysts’ expectations of $80.45 million. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. As a group, research analysts predict that Aurinia Pharmaceuticals Inc will post 0.79 earnings per share for the current fiscal year.

Aurinia Pharmaceuticals Profile

(Free Report)

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.

Featured Stories

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP).